BTK Inhibitors vs Venetoclax: Considerations for Frontline Treatment Selection in CLL
Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.
Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, How do I treat patients with relapsed/refractory multiple myeloma after…
The EORTC Projects and Services department is looking for a Services Administrator to reinforce its team. The Services Administrator will work…
Explore a discovery from researchers that could one day help tailor immunotherapy treatments for patients with multiple myeloma.
Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis.
Despite improvements in therapy, breast cancer still contributes to high mortality rates. Survival of these patients becomes progressively worse upon diagnosis with cancer-associated thrombosis (CAT).…
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Watch live to hear the latest current and emerging clinical data on the use of immunotherapy in patients with melanoma, hepatocellular carcinoma (HCC), and l…
China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.
Anticoagulants have long been fundamental in preventing and treating thromboembolic disorders, with a recent shift of focus towards direct oral anticoagulants, thanks to their ease…
In this discussion, Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, is joined by Sanam Loghavi, MD, The University of Texas MD…